16,458 Shares in Cencora, Inc. $COR Acquired by Indivisible Partners

Key Points

• 16,458 shares of Cencora (NYSE:COR) were acquired by Indivisible Partners in Q4, a stake valued at about $5.56 million, and roughly 97.52% of the stock is held by institutional investors.
• Cencora's May 6 quarter missed expectations—EPS $4.75 vs. $4.80 and revenue $78.36B vs. $81.09B—and the company set FY2026 guidance at $17.65–$17.90 EPS (sell-side consensus ~17.58).
• Analyst sentiment is a Moderate Buy, with 12 Buy and 3 Hold ratings and an average price target of $398.17 following multiple recent upgrades.

Indivisible Partners acquired a new position in Cencora, Inc. (NYSE:COR - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 16,458 shares of the company's stock, valued at approximately $5,559,000.

Several other hedge funds also recently added to or reduced their stakes in the business. United Bank lifted its stake in Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company's stock worth $2,109,000 after purchasing an additional 305 shares in the last quarter. Nebula Research & Development LLC acquired a new position in Cencora during the second quarter worth $595,000. Treasurer of the State of North Carolina lifted its stake in Cencora by 7.9% during the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company's stock worth $25,647,000 after purchasing an additional 6,244 shares in the last quarter. Diversify Advisory Services LLC lifted its stake in Cencora by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company's stock worth $747,000 after purchasing an additional 1,253 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in Cencora by 26.0% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company's stock worth $22,025,000 after purchasing an additional 15,154 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Get Cencora SMS alerts:

Sign Up

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Robert W. Baird set a $415.00 price target on Cencora in a research note on Tuesday, January 13th. Weiss Ratings raised shares of Cencora from a "hold (c+)" rating to a "buy (b)" rating in a research note on Thursday, February 5th. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $417.00 to $419.00 and gave the company an "overweight" rating in a research note on Tuesday, February 10th. Jefferies Financial Group raised shares of Cencora from an "underperform" rating to a "buy" rating in a research note on Thursday, January 22nd. Finally, William Blair assumed coverage on shares of Cencora in a research note on Tuesday, April 28th. They issued a "market perform" rating for the company. Twelve analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $398.17.

Cencora Trading Up 0.7%

NYSE:COR opened at $305.89 on Wednesday. The firm has a market cap of $59.50 billion, a PE ratio of 36.77, a price-to-earnings-growth ratio of 1.42 and a beta of 0.64. The stock has a fifty day moving average price of $332.27 and a 200 day moving average price of $343.21. Cencora, Inc. has a 12-month low of $271.00 and a 12-month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR - Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.80 by ($0.05). The company had revenue of $78.36 billion during the quarter, compared to analysts' expectations of $81.09 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts anticipate that Cencora, Inc. will post 17.58 earnings per share for the current fiscal year.

Cencora Company Profile

Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.